Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Satralizumab versus placebo in NMDAR or LGI1 autoimmune encephalitis
NL-OMON60550Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in anti-NMDA receptor encephalitis and Anti-leucine-rich glioma inactivated 1 encephalitis comparing Satralizumab arm with Placebo arm (2 arms). Primary endpoints: Proportion of participants with mRS improvement and no rescue therapy at Week 24 and Proportion of participants with mRS improvement and no rescue therapy at Week 52. Started Oct 2023; status: completed.
02
Drugs
satralizumab
03
Conditions
anti-NMDA receptor encephalitisAnti-leucine-rich glioma inactivated 1 encephalitis
Beyond the preview
Go deeper on NL-OMON60550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60550.